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Abstract  
As part of its Single Technology Appraisal (STA) process, the UK National Institute for Health and 
Care Excellence (NICE) invited the manufacturer (EUSA Pharma) of dinutuximab beta (Qarziba®) to 
submit evidence of its clinical- and cost-effectiveness for treating neuroblastoma. The BMJ 
Technology Assessment Group (BMJ-TAG) was commissioned to act as the Evidence Review Group 
(ERG), reviewing the submission from the company. The Decision Support Unit (DSU) was 
commissioned to review additional evidence submitted by the company and to undertake further 
DQDO\VHV7KLVDUWLFOHSUHVHQWVWKHFULWLFDOUHYLHZRIWKHFRPSDQ\¶VVXEPLVVLRQVE\WKH(5*DQG'68
further analyses undertaken by the DSU, and the outcome of the NICE guidance. The clinical 
effectiveness for dinutuximab beta was derived from a phase III randomised controlled trial (RCT) 
which assessed the safety and efficacy of the addition of interleukin-2 (IL-2) to dinutuximab beta plus 
isotretinoin. This trial did not inform the relative effectiveness of dinutuximab beta versus isotretinoin 
alone, which was established practice in the UK for maintenance treatment. In the absence of direct 
evidence, the company initially conducted a naïve indirect treatment comparison against a historical 
control, and later performed a matching-adjusted indirect comparison (MAIC) against the isotretinoin 
arm of an RCT comparing dinutuximab alpha and isotretinoin. The company submitted a partitioned 
survival analysis model that calculated the incremental cost-effectiveness of dinutuximab beta versus 
LVRWUHWLQRLQ7KHFRPSDQ\¶VRULJLQDOLQFUHPHQWDOFRVW-effectiveness ratio (ICER) was £22,338 per 
quality-adjusted life year (QALY) gained+RZHYHUWKH(5*ZHUHFRQFHUQHGWKDWWKHFRPSDQ\¶V
ICER was not suitable for decision-making, thus carried initial exploratory analysis as a first step to 
RYHUFRPHWKHQDwYHHVWLPDWLRQRIWUHDWPHQWHIIHFWLYHQHVVLQWKHPRGHO7KH(5*¶VDQDO\VLVHVWLPDWHG
an ICER of £111,858 per QALY gained. In their revised analysis incorporating the MAIC and other 
FKDQJHVDVUHTXHVWHGE\WKHDSSUDLVDOFRPPLWWHHWKHFRPSDQ\¶V,&(5ZDV per QALY 
gained. When the DSU incorporated longer-term isotretinoin data and made corrections to the model, 
the ICER increased to between £62,886 and £87,164 per QALY gained depending on the choice of 
survival model. A confidential Patient Access Scheme (PAS) decreased the ICERs. The ICERs with 
the PAS were over £40,000 per QALY gained, but the NICE committee additionally considered the 
patient population and its size, the disease severity, the potential for significant survival benefit and 
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uncaptured health benefits, and recommended dinutuximab beta as a treatment option, subject to the 
company providing the agreed discount in the PAS. 
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Key Points for Decision Makers  
 There is uncertainty in the clinical- and cost-effectiveness of dinutuximab beta compared to 
isotretinoin for high-risk neuroblastoma because the clinical evidence relied on a matching-adjusted 
indirect comparison, in the absence of direct evidence. 
 There are several plausible survival models for extrapolating overall survival and event-free 
survival for dinutuximab beta, leading to uncertainty in the cost-effectiveness analysis. 
 The most plausible incremental cost-effectiveness ratio for dinutuximab beta compared to 
isotretinoin is above £40,000 per quality-adjusted life year gained, but the committee considered 
additional factors when recommending dinutuximab beta as a cost-effective treatment option.  
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1  Introduction  
The National Institute for Health and Care Excellence (NICE) provides guidance on the use of health 
technologies within the National Health Service (NHS) in England. NICE considers the clinical- and 
cost-effectiveness of a technology within its Single Technology Appraisal (STA) programme[1]. In 
the STA process, the company provides a written submission and executable economic model. These 
are reviewed by an external independent organisation, known as the Evidence Review Group (ERG). 
The NICE appraisal committee consider the evidence from the company, the ERG report, expert 
testimony and input from other consultees in developing its preliminary recommendations in the 
Appraisal Consultation Document (ACD). After publication of the ACD, the company may provide 
further analyses for rHYLHZE\WKH(5*DQGFRQVLGHUDWLRQLQGHYHORSLQJ1,&(¶VILQDOJXLGDQFHLQWKH
Final Appraisal Document (FAD). On occasions, the NICE committee may require further evidence in 
addition to that presented to the Committee, or beyond the remit of the (5*¶VUHYiewing role. In these 
instances, NICE may commission its Decision Support Unit (DSU) to review and critique additional 
evidence from the company, or to undertake new analyses. 
This paper presents a summary of the ERG[2] and DSU[3, 4] reports for the STA of dinutuximab beta 
(Qarziba®, EUSA Pharma) for neuroblastoma, the NICE guidance development and the key 
methodological issues.  
 
2  Decision Problem 
 
Neuroblastoma is a type of paediatric cancer that arises from the embryonic nervous system. 
Neuroblastoma is a rare disease, with annual incidence in the UK of between 80 and 100 cases[5]. 
Neuroblastoma is a heterogeneous disease, and children with neuroblastoma are categorised into risk 
groups (very low, low, intermediate and high) according to their disease stage[6].  
Treatment for high-risk neuroblastoma consists of three phases: induction of remission with intensive 
chemotherapy, consolidation of remission using myeloablative therapy (MAT) and haematopoietic 
stem cell transplant (SCT), and maintenance therapy with isotretinoin and anti-GD2 
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immunotherapy[6, 7].  Dinutuximab beta, an anti-GD2 immunotherapy, received its marketing 
authorisation for the treatment of high-risk neuroblastoma in children and adults, for the European 
Union in May 2017[8]. 
This STA focussed on the comparison between dinutuximab beta and isotretinoin in patients with 
high-risk neuroblastoma who achieved at least a partial response to induction therapy and who had 
MAT and SCT. The NICE final scope defined the population as patients with high-risk neuroblastoma 
who have had MAT and SCT[9]. The ERG noted that the company considered a slightly narrower 
population, as patients had to have achieved at least a partial response to induction therapy. The 
intervention, dinutuximab beta, was as per the scope. The scope listed isotretinoin and dinutuximab 
alpha as comparators, the company included isotretinoin but not dinutuximab alpha as its marketing 
authorisation was withdrawn. The ERG agreed with the choice of comparator. Outcomes included 
overall survival (OS), event-free survival (EFS), adverse events (AEs), tumour response and health-
related quality of life (HRQL). The scope listed subgroups of patients with relapsed or refractory 
disease, but the company suggested focussing only on high-risk patients who had not previously had 
dinutuximab beta, the ERG questioned the relevance of the relapsed or refractory populations and 
clinical experts confirmed that all UK relapsed or refractory patients would have already received 
dinutuximab beta.  
 
3. Clinical and cost-effectiveness evidence 
 
In this STA, the process was as follows: 
1. The company submitted its written submission and economic model[10] 
2. The ERG asked clarification questions of the company[10] 
3. The company responded to clarification questions and provided revised analyses[10] 
4. 7KH(5*SURGXFHGDUHSRUWUHYLHZLQJWKHFRPSDQ\¶VHYLGHQFH[10] 
5. 7KH1,&(DSSUDLVDOFRPPLWWHHGLVFXVVHGWKHFRPSDQ\¶VHYLGHQFHDQG(5*UHSRUW[10] 
 7 
 
6. The NICE appraisal committee requested further analyses from the company[10] 
7. The company provided further analyses[10] 
8. The DSU asked clarification questions of the company[10] 
9. The company responded to clarification questions[10] 
10. The '68SURGXFHGDUHSRUWUHYLHZLQJWKHFRPSDQ\¶VIXUWKHUDQDO\VHVDQGFRQGXFWHG
additional analyses[10]  
11. 7KH1,&(DSSUDLVDOFRPPLWWHHGLVFXVVHGWKHFRPSDQ\¶VIXUWKHUDQDO\VHVDQG'68UHSRUW, 
and developed the ACD[11] 
12. The company responded to the ACD[12] 
13. 7KH'68UHYLHZHGWKHFRPSDQ\¶VUHVSRQVHWRWKH$&'DQGFRQGXFWHGIXUWKHUDQDO\VHV[12] 
14. 7KH1,&(DSSUDLVDOFRPPLWWHHGLVFXVVHGWKHFRPSDQ\¶VUHVSRQVH'68UHSRUWDQGIXUWKHU
analyses and developed the FAD[13]. 
 
3.1  Clinical evidence submitted by the company 
 
The company provided clinical evidence for the effectiveness of dinutuximab beta in their 
submission[14]. There was one randomised controlled trial (RCT) in the high-risk population that 
included dinutuximab beta; APN311-302; but it did not compare dinutuximab beta in combination 
with isotretinoin against isotretinoin alone[15]. APN311-302 was designed to assess the efficacy and 
safety of adding interleukin-2 (IL-2) to a regimen of dinutuximab beta plus isotretinoin. APN311-302 
was an open-label, randomised, phase III multicentre study (including UK), in patients under 21 years 
of age with high risk neuroblastoma, established diagnosis according to the International 
Neuroblastoma Staging System (INSS), at least partial response to induction therapy and no prior 
chemotherapy except 1 cycle of etoposide and carboplatin. In APN311-302, 406 patients were 
randomised and 180 patients who received dinutuximab beta plus isotretinoin and 190 patients who 
received dinutuximab beta plus isotretinoin plus IL-2 were included in the analysis. Dinutuximab beta 
was administered as five 28-day cycles intravenously at a dose of 20g/m2/day over five days, and 
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isotretinoin was administered as six 28-day cycles orally at a dose of 160mg/m2/day over 14 days. 
There was no statistically significant difference in EFS or OS between the two arms at any time point. 
Three-year EFS was 55.4% for the group not receiving IL-2 and 61.2% for the group receiving IL-2. 
Three-year OS was 64.1% for the group not receiving IL-2 and 69.1% for the group receiving IL-2. 
Serious AEs were reported in 46% of patients receiving IL-2 and 27% of those not receiving IL-2, 
most commonly these were infections, pyrexia, respiratory disorders, gastrointestinal disorders and 
hypotension. Of the common AEs, 238 patients experienced infections: 106 in the group not receiving 
IL-2 (including 48 grade 3 and 2 grade 4), and 132 in the group receiving IL-2 (including 60 grade 3 
and 6 grade 4). 
In the absence of direct evidence comparing dinutuximab beta to isotretinoin alone, the company 
initially performed a naïve indirect treatment comparison to a historical control of an earlier phase of 
APN311-302 which compared busulfan and melphalan hydrochloride (BuMel) to carboplatin, 
etoposide and melphalan (CEM) as consolidation MAT, after which 450 patients received isotretinoin 
alone as maintenance treatment. This was supplemented by a narrative comparison against the 
isotretinoin arm of an RCT comparing dinutuximab alpha plus IL-2 to isotretinoin in patients with 
high-risk neuroblastoma who had a response to induction therapy and SCT in a study by Yu et al 
(2010) ([16]). In response to a request from the NICE committee, the company provided an 
unanchored matching-adjusted indirect comparison (MAIC) comparing the combined dinutuximab 
beta arms of APN311-302 against isotretinoin arm in Yu et al (2010). The MAIC adjusted for age, 
INSS stage, tumour N-myc proto-oncogene protein (MYCN) status and response before SCT.  
 
3.2  ERG and DSU critique of clinical evidence and additional analyses 
 
The ERG noted that the open-label design of APN311-302 introduced bias, the lack of pre-specified 
time-point for disease assessment meant that it is unclear whether EFS captured the exact point of 
disease progression, and that the data presented were not the Intention to Treat (ITT) population. They 
further noted that the short-term study dosing schedule was unlikely to be in line with clinical practice 
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where dinutuximab beta would be given over 10 days and not 5, and that there was a paucity of 
evidence regarding the effect of the infusion rate on outcomes. Finally, they noted the immaturity of 
the data for EFS and OS and that, therefore, there is uncertainty in determining the clinical 
effectiveness particularly regarding whether benefit would be maintained in the long term. 
In their clarification questions, the ERG proposed that a MAIC of the combined APN311-302 data 
compared to the isotretinoin arm in Yu et al (2010) was viable and would provide a more robust 
evidence base than the historical control. This was because the historical control was a retrospective 
collection of data from an essentially non-randomised study, and that the naïve indirect treatment 
comparison was subject to the same potential biases as a MAIC, and from additional confounding due 
to imbalance in the prognostic factors and effect-modifying factors. 
7KH'68UHYLHZHGWKHFRPSDQ\¶V0$,&FRPSDULQJGLQXWX[LPDEEHWDDQGisotretinoin, and 
highlighted errors in the FRPSDQ\¶V approach. The DSU reported that the number of patients used in 
calculating the proportions of patients in APN311-ZDVLQFRUUHFWDQGLJQRUHGWKDWSDWLHQWV¶
INSS status were unknown in Yu et al (2010), and categorical variables did not all have a reference 
case. The company had included the individual patient data (IPD) from APN311-302 in the economic 
model, and so the DSU corrected the errors and re-ran the MAIC. The EFS and OS for isotretinoin 
and IRUGLQXWX[LPDEEHWDIURPWKHREVHUYHGGDWDDQGWKHFRPSDQ\DQG'68¶V0$,&VDUHVKRZQLQ 
Figure 1. 
 
3.3 Cost-effectiveness evidence submitted by the company 
 
The company developed a partitioned survival analysis model with health states defined as Event-
Free, Failure and Death. The model had a short-term element, in which the proportion of patients in 
each health state was calculated from survival analysis of EFS and OS data, and a long-term element. 
Patients in the long-term element could not move from Event-Free to Failure, as it was assumed that 
patients who were Event-Free at this point were cured. The time point at which the model changed 
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from short-term to long-WHUPZDVWHUPHGWKH³FXUHWKUHVKROG´DQGZDVDVVXPHGWREH\HDUVLQWKH
base case. In the long-term model, the mortality of patients in the Event-Free state was 5.6 times the 
mortality for the general population, based on a report from the Childhood Cancer Survival Study[17] 
and the mortality of patients in the Failure state was 90% higher than patients in the Event-Free state. 
Through the STA, the company used a number of different approaches to estimate the transitions 
between states in the short-term model for dinutuximab beta and isotretinoin. Initially, the company 
used unadjusted Kaplan±Meier (KM) data for isotretinoin OS from the historical control and 
estimated EFS KM data, and took a similar approach for dinutuximab beta data. In response to the 
(5*¶VFODULILFDWLRQTXHVWLRQVWKHFRPSDQ\XVHG*RPSHUW]VXUYLYDOGLVWULEXWLRQVIRU\ears where KM 
data were not available. As an alternative, the company also provided a hazard ratio for the indirect 
comparison of dinutuximab beta versus isotretinoin for OS, adjusted for prior treatment, MYCN, age 
and INSS stage at diagnosis. Following the request from the committee to conduct the MAIC, the 
company fitted parametric models to isotretinoin OS and EFS from Yu et al (2010) and matching-
adjusted dinutuximab beta OS and EFS from APN311-302. The company used KM data for years 1±6 
and the Gompertz extrapolation beyond this.  
The company included common treatment-emergent AEs listed in the Summary of Product 
Characteristics (SmPC)[18] for dinutuximab beta (pain, hypersensitivity, severe capillary leak 
syndrome, eye problems, peripheral neuropathy, pyrexia/infection, and vomiting/diarrhoea). Data on 
the proportion of patients having AEs were based on a safety database which included high-risk and 
relapsed or refractory neuroblastoma patients[14]. In the additional analysis, the company made a 
distinction between pyrexia and infection and added grade3-4 infection rates based on APN311-302 
for the group with and without IL-2.  
The company did not initially specifically model treatment discontinuation, implicitly assuming that 
EFS was representative of time on treatment. In later analyses, the company subtracted the proportion 
of patients discontinuing due to toxicity from the EFS to estimate time on treatment.  
 11 
 
To model HRQL, the company used UK general population norms for EuroQol-5 Dimension (EQ-
5D)[19] and applied a percentage decrement for having neuroblastoma (the Event-Free state) and 
recurrent disease (the Failure state). The company initially used a logistic regression to estimate 
general population norms, but later replaced this with a published algorithm[20]. The decrement for 
Event-Free was 12.5%, calculated from the relationship between high-risk neuroblastoma utilities and 
general population utilities measures using Health Utilities Index (HUI) 3. The decrement for the 
Failure state was 41.7%, calculated from the relationship between utility for recurrent disease[21] and 
the general population[22]. The company did not include utility decrements for AEs, due to a lack of 
available data.  
The company included costs for drug acquisition, administration and hospitalisation, concomitant 
medication, disease management and AEs, valued at 2016 prices. Drug acquisition costs were based 
on unit prices and the number of units consumed based on body surface area (BSA). The company 
initially used the median BSA from APN311-302, but later revised this to use a weighted average cost 
based on the distribution of patients across BSA categories. The company initially included the costs 
of concomitant IL-2 for all patients with isotretinoin and dinutuximab beta, which was later removed 
as there was no anticipated clinical benefit and clinicians advised that IL-2 would not be co-prescribed 
as standard. Administration costs for dinutuximab beta were initially assumed to involve 7.5 inpatient 
hospital days for cycle 1 and 2.5 for cycle 2, with the remainder of cycles in an outpatient setting. 
This was later revised to 10 inpatient hospital days in cycle 1 and 5 in cycle 2. The company included 
the costs for concomitant medication to manage pain and allergic reactions associated with 
dinutuximab beta treatment. Resource use for the Event-Free state was based on a study of healthcare 
resource use in the British Childhood Cancer Survivor Study[23] and costed using NHS reference 
costs. Costs for the Failure state included treatment with topotecan and cyclophosphamide and 
filgrastim ± these were initially applied until death, but later revised to be applied for one year, 
beyond which the resource use for the Event-Free state was applied. Costs for AEs were included, 
costed using NHS reference costs.  
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3.4  ERG and DSU critique of cost-effectiveness evidence and additional analyses 
 
The ERG and DSU agreed with the model structure but had concerns about a number of model inputs. 
The ERG were severely concerned with the estimation of treatment effect, specifically regarding the 
assumptions used in the initial approach, the survival analysis method used to fit Gompertz 
distributions and the use of the naïve indirect treatment comparison.  
The ERG disagreed with carrying out a naive analysis of treatment effectiveness and felt that the 
comSDQ\¶VPRGHOZDVQRWVXLWDEOHIRUGHFLVLRQ making. The ERG undertook an exploratory analysis 
for illustrative purpose only, estimating a hazard ratio for isotretinoin EFS and OS relative to 
dinutuximab beta (based on the relationship between dinutuximab alpha and isotretinoin) and using 
the extrapolated Gompertz distribution instead of KM data for dinutuximab beta.  
The DSU had similar concerns regarding the methods for survival analysis following the MAIC, 
which used least squares optimisation to fit parametric models. The DSU noted that the ERG had 
identified KM data from a later cut-off of the study comparing isotretinoin with dinutuximab 
alpha[16] which reported 12 years of EFS and OS data for isotretinoin[24]. The DSU performed 
survival analysis of the MAIC-adjusted dinutuximab beta data ± this was not necessary for 
isotretinoin as the KM data could be used directly in the model with no requirement for extrapolation. 
In their survival analysis, the DSU considered standard parametric models and flexible spline-based 
models to allow for more complex hazard functions. According to statistical measures of goodness of 
fit (Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC)) and visual 
inspection, the Generalised Gamma, Gompertz, log normal and spline models had the best internal 
validity for OS, and the Generalised gamma and spline models for EFS. Clinical experts advised that 
events after five years would be rare, suggesting that models which flattened somewhat after five 
years may be most appropriate. The DSU noted that if events after five years were impossible, models 
which were completely flat after five years would equate to using a five-year cure threshold. Longer-
term data for dinutuximab beta were not available, but 12-year data for dinutuximab alpha were[25]. 
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Given the expected similarities between dinutuximab alpha and beta, the DSU used the shape of the 
best-fitting dinutuximab alpha models and the relationship between dinutuximab alpha and 
isotretinoin to inform model selection[25]. The DSU therefore felt that the Gompertz and spline with 
2 knots for OS and the Gompertz and spline with 1 knot for EFS should be considered potentially 
plausible. $FRPSDULVRQRIWKH'68DQGFRPSDQ\¶V26PRGHOVDUHSUHVHQWHGLQ)LJXUHDQG()6
models in Figure 3.  
The ERG had concerns about the source of AE data and whether it was applicable to patients 
receiving dinutuximab beta as a continuous infusion, but found the impact of scenario analysis was 
negligible. The ERG noted that most patients in the SmPC safety dataset received IL-2, and that IL-2 
increased the risk of AEs7KH'68FRQVLGHUHGWKDWWKHFRPSDQ\¶VDGMXVWPHQWWRPRGHOLQIHFWLRQ
rates separately for dinutuximab beta with and without IL-2 was appropriate.  
The DSU considered that the compaQ\¶VDSSURDFKWRGLVFRQWLQXDWLRQZDVLQDFFXUDWHDQGSUHIHUUHGWR
use the proportion of patients treated per cycle reported in APN311-302.    
The ERG critiqued the cost data, considering a scenario analysis including wastage for gabapentin (a 
concomitant medication which excluded wastage) and using the cost of a hospital day for 
chemotherapy administration rather than chemotherapy procurement costs. The ERG further noted 
that treatment in the failure state was likely overestimated as it should only be given until further 
disease progression or one year[26]7KH'68FRQVLGHUHGWKDWWKHFRPSDQ\¶VUHYLVHGDQDO\VLVZKLFK
incorporated these changes, was appropriate.  
The ERG were concerned about the logistic regression for UK general population utility norms, 
requesting that the published algorithm[20] be used instead, so the DSU considered that the 
FRPSDQ\¶V revised analysis using this algorithm was appropriate. The ERG had concerns regarding 
the utility decrements, specifically that one study[22] used HUI3 which was not developed for use in 
children, and that this was combined with the HUI2 values in another study[21] when the measures 
PD\QRWEHFRPSDUDEOH)XUWKHUPRUHWKHFRPSDQ\¶VDSSURDFKDVVXPHGWKDWWKHSRSXODWLRQVLQthe 
two studies were comparable, despite differences in age, and that patients in the second study did not 
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have neuroblastoma[21]. Overall, the ERG were unable to draw final conclusions as to which utility 
values should be used, and considered it a source of uncertainty. The ERG noted that excluding the 
impact of AEs on HRQL may overestimate the QALY gain for dinutuximab beta, but considered that 
this impact would be minimal. 
The ERG corrected the dinutuximab beta administration costs in the model and stated that they would 
have preferred the drug acquisition costs to use an average number of vials according to the 
distribution of BSA, which tKHFRPSDQ\DGGUHVVHGLQWKHLUUHYLVHGDQDO\VLV6LPLODUO\WKHFRPSDQ\¶V
UHYLVHGDQDO\VLVDGGUHVVHGWKH(5*¶VFRQFHUQVDERXWWKHFRVWVRIFKHPRWKHUDS\DGPLQLVWUDWLRQDQG
wastage of concomitant medication. 
7KHFRPSDQ\¶VEDVHFDVH incremental cost-effectiveness ratio (ICER) was £22,338 per QALY gained 
in their original submission, DQGWKH(5*¶VFRUUHFWLRQVLQFUHDVHGWKLVWR per QALY gained.  
,QWKH(5*¶VH[SORUDWRU\DQDO\VLVthe ICER was £111,858 per QALY gained. After addressing the 
changes requested by the appraisal committeeWKHFRPSDQ\¶V,&(5ZDV24,661 per QALY gained. 
Taking into consideration the corrections and revisions made by the company, ERG and DSU, the 
'68¶VILQDODQDO\VLVHVWLPDWHGWKDWWKH mean deterministic ICER ranged from £62,886 to £87,164 
(probabilistic: £69,000 to £80,000) per QALY gained depending on the choice of survival model for 
OS and EFS (Table 1). A confidential Patient Access Scheme (PAS) discount decreased the ICERs.  
 
4.  Key methodological issues 
The key methodological issues in the evidence base were the indirect treatment comparison and 
extrapolation of EFS and OS. Naïve indirect treatment comparisons are inherently biased, and while a 
MAIC can address the bias arising from imbalance in the prognostic factors and measured treatment-
effect modifiers it is not without limitations[27].  
Extrapolation beyond observed data is uncertain and therefore methods to analyse survival data 
should be as robust as possible and alternative extrapolations should be considered. The approach 
taken by the company was not transparent, and it transpired, not correct. Extrapolations are less 
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uncertain where longer-term data are used. The approach taken by the DSU, using the most recent 
GDWDIRULVRWUHWLQRLQLQFUHDVHGWKH,&(5VVXEVWDQWLDOO\7KH'68¶VVFHQDULRDQDO\VHVGHPRQVWUDWHG
that using alternative plausible survival functions could increase the ICER by over £20,000 per QALY 
gained. 
 
5. NICE guidance  
On 22 August 2018, NICE recommended dinutuximab beta as an option for treating high-risk 
neuroblastoma in patients aged 12 months and over whose disease has at least partially responded to 
induction chemotherapy, followed by MAT and stem cell transplant only if they have not already had 
anti-GD2 immunotherapy and the company provides dinutuximab beta according to the commercial 
arrangement. 
 
5.1  Consideration of Clinical and Cost-Effectiveness Issues in the Final Appraisal Determination 
 
This section presents a summary of the key issues considered by the committee. A full discussion of 
all issues is presented in the FAD[13]. The committee felt that the evidence for relapsed or refractory 
neuroblastoma was not relevant and focussed only on high risk neuroblastoma.  
 
Consideration of clinical effectiveness 
 
The committee concluded that despite the limitations of immature data, lack of fixed cut-off data and 
potential biases of the open-label design, APN311-302 represented the best source of evidence for 
dinutuximab beta, but it did not inform the relative effectiveness of dinutuximab beta compared to 
isotretinoin. The committee noted that the MAIC showed dinutuximab beta improved EFS and OS 
compared with isotretinoin, and that the later cut-off of isotretinoin data was most appropriate for the 
comparator data. 
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The committee noted the non-significant difference for EFS and OS between the groups with and 
without IL-2 in APN311-302, and clinical experts advised that IL-2 would not be used in clinical 
practice. The committee noted that dinutuximab beta was associated with AEs, but that these were 
more common when given in combination with IL-2.  
 
Consideration of cost effectiveness 
 
The committee accepted the structure of the economic model. The committee noted that the long-term 
benefit of dinutuximab beta was uncertain and so considered a range of extrapolations for EFS and 
OS, noting that Gompertz and Spline models are the most plausible for both. The committee preferred 
a 10-year cure threshold, but considered a range of thresholds in its decision making. The committee 
felt that the cost, utility, discount rate and discontinuation data in the final DSU model were 
appropriate.  
 
End of Life criteria 
 
The committee considered that dinutuximab beta did not meet end-of-life criteria[1]. The modelled 
life expectancy of isotretinoin alone was approximately 31 to 34 years so did not meet the criterion for 
short life-expectancy, although the survival gain was in the range of 3±5 years which did meet the 
criterion for survival gain. The committee recognised that the survival gain was substantial, but due to 
the uncertainty, could not be confident of the extent of proportional gain in relation to life expectancy.  
6. Conclusion 
The committee considered a range of ICERs, given the uncertainty in the long-term benefit of 
GLQXWX[LPDEEHWD7KHFRPPLWWHHFRQVLGHUHGWKH,&(5VIRUWKHFRPPLWWHH¶VSUHIHUUHGDVVXPSWLRQV
were above £40,000 per QALY gained and above the range normally considered cost-effective by 
NICE. However, in addition to considering the ICERs, the committee considered the patient 
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population and its size, the disease severity, the potential for significant survival benefit, and effect of 
end of life costs (decreasing ICERs by £1,000 per QALY gained) and uncaptured benefits not 
included in the ICERs. The uncaptured health-related benefits were noted to include the effect of 
neuroblastoma on reducing quality of life for young patients and their families and the impact of 
bereavement on families. The committee was prepared to be flexible in its decision making given the 
rarity and severity of the disease, and noted the importance of potentially generating life-long health 
benefits in the patient population. Considering all of these factors, the committee was able to 
recommend dinutuximab beta as a cost-effective treatment option.  
 
Data Availability Statement 
The model used in the current study are not publically available as were part of the NICE appraisal 
process. 
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Figure captions and legends 
Figure 1: Matching-adjusted indirect comparison results 
DSU: Decision Support Unit, ESS: effective sample size, MAIC: matching-adjusted indirect 
comparison 
 
Figure 2: Comparison of company and DSU overall survival data 
 
DSU: Decision Support Unit, OS: overall survival 
 
Figure 3: Comparison of company and DSU event-free survival data 
 
DSU: Decision Support Unit, EFS: event-free survival 
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Table 1: Results of final analysis 
 Total Incremental ICER 
(per 
QALY 
gained) Cost QALYs LYs Cost QALYs LYs 
OS: Gompertz. EFS: spline k=1, scale=odds 
Isotretinoin £60,459 16.45 31.58     
Dinutuximab 
beta 
£224,234 18.61 35.99 £163,775 2.16 4.40 £75,831 
OS: spline k=2, scale=hazards. EFS: spline k=1, scale=odds 
Isotretinoin £60,459 16.45 31.58     
Dinutuximab 
beta 
£224,898 18.34 35.17 £164,439 1.89 3.59 £87,164 
OS: Gompertz. EFS: Gompertz 
Isotretinoin £60,459 16.45 31.58     
Dinutuximab 
beta 
£220,213 18.99 36.26 £159,753 2.54 4.68 £62,886 
OS: spline k=2, scale=hazards. EFS: Gompertz 
Isotretinoin £60,459 16.45 31.58     
Dinutuximab 
beta 
£220,877 18.72 35.45 £160,417 2.27 3.86 £70,757 
EFS: event-free survival, ICER: incremental cost-effectiveness ratio, LYs: life years, OS: overall survival, 
QALY: quality adjusted life years. LYs are undiscounted. Costs and QALYs are discounted at 1.5% per annum.  
